EXHIBIT 107
EX-FILING FEES
Calculation of Filing Fee Tables
S-1
(Form Type)
DERMATA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Registrant Name in English, if applicable
(Translation of Registrant’s Name into English)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
| Security |
| Fee |
|
| Maximum Price(1) |
|
| Fee Rate |
| Amount of Fee(2) |
| |||
| Fees to Be Paid |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| Units consisting of: |
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| Common Stock, $0.0001 par value per share (3) |
|
| 457 | (o) |
| $ | 11,500,000.00 |
|
| $92.70 per $1,000,000 |
| $ | 1,1178.80 |
|
|
|
| Warrants to purchase Common Stock (4) |
|
| 457 | (g) |
| ____ |
|
|
|
| $ | 0.00 |
| |
| Common Stock issuable upon exercise of the Warrants |
|
|
|
| 457 | (o) |
| $ | 11,500,000.00 |
|
| $92.70 per $1,000,000 |
| $ | 1,1178.80 |
|
| Pre-funded warrants to purchase shares of common stock and common stock issuable upon exercise thereof (5) |
|
|
|
| 457 | (g) |
| ____ |
|
|
|
| $ | 0.00 |
| |
| TOTAL |
|
|
|
|
|
|
| $ | 23,000,000.00 |
|
|
|
| $ | 2,235.60 | (6) |
| (1)
| Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).
|
| (2)
| Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
|
| (3)
| Includes shares of Common Stock and/or warrants which may be issued on exercise of a 45-day option granted to the underwriter to cover overallotments, if any.
|
| (4)
| No separate registration fee required pursuant to Rule 457(g) under the Securities Act.
|
| (5)
| The proposed maximum aggregate offering price of the Common Stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the Common Stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the Common Stock and pre-funded warrants (including the Common Stock issuable upon exercise of the pre-funded warrants), if any, is $11,500,000 (including the underwriter’s option to purchase additional shares of common stock). |
|
|
|
| (6) | Previously paid. |